Data Sheet

Product Name:	Duvelisib
Cat. No.:	HY-17044
CAS No.:	1201438-56-3
Molecular Formula:	$C_{22}H_{17}ClN_6O$
Molecular Weight:	416.86
Target:	PI3K
Pathway:	PI3K/Akt/mTOR
Solubility:	DMSO: ≥ 41 mg/mL



BIOLOGICAL ACTIVITY:

Duvelisib is a selectivite **p100δ** inhibitor with IC_{50} of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.

IC50 & Target: IC50: 2.5 nM (p110δ), 27.4 nM (p110γ), 85 nM (p110β), 1602 nM (p110α)[2]

In Vitro: PI3Kδ and PI3Kγ inhibition with IPI–145 has anti–proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre–treatment of AML cells with IPI–145 inhibits both adhesion and migration of AML blasts to bone marrow stromal cells[1].

References:

[1]. Pillinger G, et al. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget. 2016 Jun 28;7(26):39784–39795.

[2]. G?ckeritz E, et al. Efficacy of phosphatidylinositol–3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015 Nov 1;137(9):2234–42.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA